Initial ex-vivo testing using a porcine skin model showed a 95% bacterial reduction within four hours, with sustained effectiveness over 24 hours
Inspira Technologies (NASDAQ: IINN) has reported promising pre-clinical results for its bio-electronic anti-bacterial IV dressing technology, developed in collaboration with Ennocure MedTech Ltd. The innovative solution aims to combat bloodstream infections, a critical issue affecting an estimated 250,000 patients worldwide each year due to contaminated intravenous (IV) lines.
In ex-vivo testing using a porcine skin model, the bio-electronic patch demonstrated a 95% bacterial reduction within four hours, with continued effectiveness over a 24-hour period. Unlike traditional chemical-based dressings, this breakthrough technology employs physical electric stimulation to prevent bacterial colonization, reducing the risk of infections without relying on antimicrobial agents.
CEO Dagi Ben-Noon emphasized the significance of this milestone, highlighting the potential benefits for critical care settings. The bio-electronic dressing is being designed to address key challenges, including:
- Reducing bacterial growth without chemicals
- Extending wear time, minimizing frequent dressing changes
- Protecting both skin surface and cannula areas
- Enabling real-time monitoring for better patient management
Testing followed AATCC TM100 antimicrobial standards, showing consistent bacterial reduction under active patches compared to controls. As the company advances development, this technology could redefine infection prevention strategies in hospitals and enhance patient safety worldwide.
Read original press release here
You might like this article:Coca-Cola Tops Estimates with Strong Q4 Results
